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Abstract 
Introduction: Multiple endocrine neoplasia type 1 (MEN1) has been causing problems for clinicians since it was first described in 1954 by 
Wermer. Not only its rarity, but also its variable clinical manifestations and lack of genotype-phenotype correlation make it hard to establish 
evidence-based guidelines for the management of this syndrome. Nationwide registers and population-based research are the best means 
to improve knowledge about this rare disease. As yet, there is no example of such research in the Polish population of MEN1 patients.
Material and methods: We performed a retrospective analysis of clinical and genetic data of patients diagnosed with MEN1 syndrome 
and followed-up in two polish referral centres in the years 1994–2018.
Results: We analysed 79 patients, of whom the majority were women. The mean age of the patient population was 43 years, mean age at 
MEN1 diagnosis was 37.95 years, and mean interval from initial symptoms to MEN1 diagnosis was 6.93 years. Primary hyperparathyroid-
ism (PHP), gastroenteropancreatic neuroendocrine tumour (GEP-NET), and pituitary adenoma (PA) developed in 90%, 52%, and 47% of 
patients, respectively. The dominance of insulinoma with low prevalence of gastrinoma is the most vivid difference, when compared to 
previously described populations. Moreover, we found 3.5-fold higher risk of developing a pituitary tumour in patients with a frameshift 
mutation with the STOP codon of the MEN1 gene.
Conclusions: The Polish population of patients with MEN1 is different than previously described European and Asian populations, 
primarily in prevalence of functional NETs. A frameshift mutation with the STOP codon of the MEN1 gene significantly increases the 
risk of PA. Further studies with a larger cohort of patients are needed to fully describe the Polish population and improve diagnosis and 
management of the syndrome. (Endokrynol Pol 2019; 70 (5): 385–391)
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Introduction
Multiple Endocrine Neoplasia type 1 (MEN1) is a rare, 
genetically conditioned syndrome predisposing to 
primary hyperparathyroidism (PHP), neuroendocrine 
tumours of the gastric tract (GEP-NET), pituitary ad-
enomas (PA), and other endocrine and non-endocrine 
tumours. This disorder is caused by germline mutation 
of a tumour suppressor gene that is located at 11q13 
locus and encodes a protein called menin. The majority 
of cases are familial, with an autosomal-dominant in-
heritance pattern, but in approximately 10% it can also 
appear sporadically due to de novo mutations [1]. The 
estimated prevalence of MEN1 in post-mortem studies 
is 0.25% and in vivo is about 2–3 per 100,000 individuals 
[1–3]. What seems to be most important for the patients 
is an increased risk of premature death and impaired 
quality of life, related to the syndrome [4–8].
Due to the sparsity of the syndrome, it is challeng-
ing to perform high-quality research and then establish 
evidence-based guidelines for therapy [6, 9]. Therefore, 
therapeutic schemes of non-genetically conditioned 
endocrine tumours have been used in such cases, in 
spite of remarkable differences [10].
The need for nationwide cohort studies and national 
registers of rare diseases has been mentioned in many 
papers [9, 11, 12], and now we have such examples in 
European and Asian populations [4, 13–16]. Despite 
these multi-centre studies, which analyse large groups 
of patients (from 258 to 734), there have also been pa-
pers presenting single-centre experiences [17, 18]. In 
all of these studies, female dominance of up to 64% is 
noted, and the prevalence of typical tumours varies at 
77–96%, 46–59%, and 32–53% for PHP, GEP-NET, and 
PA, respectively. None of these research papers reports 
a significant correlation between the genotype and 
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Results
By the end of December 2018, 95 patients met the diag-
nostic criteria of MEN1 syndrome and were included 
in the database. In 15 cases (16%) only the information 
about sex, age, family history, and type of genetic muta-
tion was provided, and one case was lost to follow-up. 
These cases were excluded from further analysis. 
Patients general characteristics
Out of 79 registered patients 59.49% (47 patients) 
were women and 40.51% (32 patients) were men, with 
a mean age of 43.00 (SD 16.21) years and median age 
of 42 years. Faxmily history of MEN1 syndrome was 
present in 67.09% of patients, from whom 18 different 
families were noted. 
The mean age at MEN1 diagnosis was 37.95 
(SD ± 15.87) years, and the median age was 36.5 
years. The mean age at MEN 1 diagnosis in subgroups of 
index cases and family members was 38.63 (SD ± 14.13) 
and 36.6 (SD ± 18.59) years, respectively. All of the 
general data about patients are presented in Table I. 
In most of the cases, the initial symptoms were 
caused by PHP (renal stones, bone fractures, randomly 
diagnosed hypercalcaemia, or parathyroid tumour in 
imaging study). The prevalence of all of the observed 
initial symptoms is presented in Figure 1. The mean 
interval from the initial symptoms to MEN1 diagnosis 
was 6.93 (SD ± 8.27) years. Delays between the diag-
nosis of a particular tumour and MEN1 are presented 
in Table II.  
Prevalence of tumours
Primary hyperparathyroidism was the most prevalent 
MEN1-associated lesion. It occurred in 71 (89.87%) 
cases and was the initial lesion in 37 cases. The mean 
age at PHP diagnosis was 35.99 (SD ± 14.00) years with 
a mean delay of 2.49 (SD ± 4.80) years to MEN1 diagno-
sis. Surgery was performed in 74.65% of patients. Out 
of these, 77.36% had a subtotal parathyroid excision; 
phenotype. However, the cohort studies are suscep-
tible to different kinds of bias, including selection and 
information [6]. 
The aims of this study were clarification of the 
clinical and genetic features of Polish patients with 
MEN1 and an attempt to establish a genotype-phe-
notype correlation. To the best of our knowledge, it 
is the first research to perform such an evaluation in 
recent years. 
Material and methods
We retrospectively analysed clinical and genetic data collected be-
tween the years 2004 and 2018 in patients affected by MEN1. All of 
the data are from two referral endocrinological centres in Poland: 
— Department of Nuclear Medicine and Endocrine Oncology, Ma-
ria Sklodowska-Curie Institute – Oncology Centre, Gliwice Branch;
— Department of Internal Diseases and Endocrinology, Medical 
University of Warsaw.
We gathered information about the following: date of birth, 
gender, first MEN1 manifestation (type and age of onset), age at 
MEN1 diagnosis, family history, all MEN1-associated endocrine 
tumours, past and current treatment, and type of MEN1 gene 
mutation.
MEN1 diagnosis was established according to current guidelines 
[1]. Nevertheless, patients with clinical diagnosis but negative 
genetic test for a MEN1 gene mutation were not included in the 
data base. In 17 patients diagnosed before 2012 we used the previ-
ous guidelines [19]. 
Mutational analysis of the MEN1 gene was undertaken in all of the 
patients suspected of having MEN1 syndrome according to clinical 
symptoms. PCR-based Sanger sequencing of genomic DNA from 
a peripheral blood sample was performed. In all of the patients, 
exons 2–10 of the MEN1 gene and introns involved in the alterna-
tive splicing process were analysed. Next Generation Sequencing 
(NGS) and Multiplex ligation-dependent probe amplification 
(MLPA) were introduced in 2017 and used in mutational analysis 
in the patients previously considered negative for a MEN1 gene 
mutation in Sanger sequencing.
When a patient was positive for a MEN1 gene mutation, mutational 
analysis was performed in first-line family members as well.
The data are presented as mean with standard deviation (SD), 
median, and percentage. Logistic regression was used to assess the 
impact of the mutation type and the exon involved in the mutation 
on the occurrence of the studied clinical events. The strength of the 
association between the analysed variables and the clinical event 
was expressed as a classical odds ratio (OR). For all the statistical 
analysis performed, p < 0.05 was considered significant.
Table I. General characteristics of population
All Index cases Family members
Sex
W: 47 (59.49%) 
M: 32 (40.51%)
W: 33 (67.35%)
M: 16 (32.65%)
W: 14 (46.67%)
M: 16 (53.33%)
Mean age [years] 43  SD ± 16.21
44.61  
SD ± 14.89
36.6  
SD ± 18.59
Median age [years] 42 42 42
Mean age at MEN1 diagnosis 
[years]
37.95  
SD ± 15.87
38.63  
SD ± 14.13
36.6  
SD ± 18.59
W — women; M — men; SD — standard deviation
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15.09% had a total parathyroidectomy and 43.40% had 
two or more procedures.
GEP-NET appeared in 41 cases (51.90%) and was 
the initial lesion in 13 cases. The mean age at GEP-NET 
diagnosis was 41.2 (SD ± 14.45) years with a mean 
delay of 1.45 (SD ± 5.43) years to MEN1 diagnosis. In 
40 cases it was a pancreatic neuroendocrine tumour 
(pNET), with concomitant neuroendocrine tumour of 
the duodenum in two patients. In one case there was 
no identified origin of the tumour. Hormonal analysis 
revealed 26.83% of functional tumours; the majority 
being insulinoma (19.51%), followed by gastrinoma 
(7.32%), and glucagonoma (2.44%). There was no 
confirmed VIP-oma. In 56.10% of patients surgery was 
performed. Out of these, 30.43% had a tumour enucle-
ation; 60.87% had a distal pancreatectomy, and only 
one patient had total pancreatectomy. A pharmacologi-
cal approach, with somatostatin analogues, was noted 
in 39.02% of patients. Other neuroendocrine tumours 
were observed in five cases (6.33%). Three of them were 
located in the lungs, one in the retroperitoneal space, 
and one in the stomach.
Pituitary adenoma occurred in 37 (46.84%) patients 
and was the initial lesion in only seven cases. More than 
half of the lesions were classified as microadenoma. The 
mean age at PA diagnosis was 36.72 (SD ± 15.35) years 
with a mean delay of 1.6 (SD ± 5.85) years to MEN1 
diagnosis. Abnormal hormonal secretion was observed 
in 62.16% of tumours with the dominance of prolactin 
(43.24%) followed by GH (10.81%), ACTH (8.11%), and 
LH and FSH (both 2.7%). Treatment consisted of surgery 
in 37.84% of patients and dopamine-agonist therapy 
in 45.95% of cases. 
Five patients (6.33%) did not present any typical 
MEN1 tumours. All of the data about the prevalence and 
characteristics of the lesions are presented in Table III.
Figure 1. Prevalence of initial symptoms in the population. GTS — gastric tract symptoms (abdominal pain, peptic ulcers, diarrhoea); 
PNP — primary hyperparathyroidism; GEP-NET — gastroenteropancreatic neuroendocrine tumours; PA — pituitary adenoma
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Table II. Delays between onset of the first symptoms and diagnosis of particular tumours to MEN1 diagnosis
All Index cases Family members
First symptoms-MEN1 [years] 6.39  SD ± 8.27
7.83  
SD ± 8.09
5.0  
SD ± 8.5
PNP-MEN1 [years] 2.49  SD ± 4.8
3.2  
SD ± 5.59
1.17  
SD ± 2.35
GEP-NET-MEN1 [years] 1.45  SD ± 5.43
1.73  
SD ± 6.22
0.6  
SD ± 1.43
PA-MEN1 [years] 1.6  SD ± 5.85
2.67  
SD ± 6.62
–0.73  
SD ± 2.57
PNP — primary hyperparathyroidism; GEP-NET — gastroenteropancreatic neuroendocrine; MEN1 — multiple endocrine neoplasia type 1; PA — pituitary adenoma
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Genetic data
All of the patients had MEN1 gene mutation analysis 
performed, but we did not receive a specific descrip-
tion of gene mutation in two cases referred from 
other departments, so they were excluded from further 
statistical analysis. Prevalence of types of mutations 
and involved exons is presented in Figures 2 and 3, 
respectively. We found a statistically significant, 3.5-fold 
higher risk of developing the pituitary tumour when 
frameshift mutation with the STOP codon appeared. 
The estimates from the univariate and multivariate 
regressions are displayed in Table IV. 
Discussion
The aim of the study was to evaluate the Polish popula-
tion of MEN1 patients and to seek any genotype-pheno-
type correlations. The Centre of Oncology in Gliwice and 
the Medical University of Warsaw are tertiary referral 
centres where genetic analysis of the MEN1 gene is per-
formed and patients from all over the country are treated. 
In recent years, there has been considerable interest 
in population-based studies analysing MEN1 patients, 
resulting in many papers describing European and 
Asian populations [4, 13–18]. Until now, mostly papers 
describing single cases of polish patients with MEN1 
were published [20, 21]. We found only one research 
paper describing a Polish population. Krassowski char-
acterised a smaller number of patients from a single 
centre and diagnosed them on the basis of Gubbio Con-
sensus. Patients were diagnosed at a younger age and 
the reported prevalence of typical lesions was higher, 
but the same tendency in insulinoma dominance was 
noticed [22].
Although genetic determination of disease should 
result in equal prevalence in both sexes, we observed 
female dominance, similarly to previously published 
population-based studies [13, 15, 17]. We found that the 
mean age at MEN1 diagnosis was only slightly higher 
for index cases than for family members. Our results, 
compared with other papers, suggest that we usually 
establish a MEN1 diagnosis earlier, and there is a smaller 
Table III. Characteristics of MEN1-associated tumours
Prevalence Mean age at diagnosis [years]
Prevalence of 
functional tumours Surgery Pharmacotherapy
PHP 71 (89.87%) 35.99  SD ± 14.00 – 53 (74.65%) NA
GEP-NET 41 (51.90%) 41.20  SD ± 14.45 26.83% 23 (56.10%) 16 (39.02%)
PA 37 (46.84%) 36.72  SD ± 15.35 62.16% 14 (37.84%) 17 (45.95%)
AA 22 (27.85%) NA 0% 18.18% NA
Carcinoid 5 (6.33%) NA NA NA NA
PNP — primary hyperparathyroidism; GEP-NET — gastroenteropancreatic neuroendocrine tumours; PA — pituitary adenoma; AA — adrenal adenoma; SD — standard 
deviation; NA — not assessed
Figure 2. Prevalence of particular types of MEN1 gene mutations
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difference between the age at diagnosis in index cases 
and family members [13, 14, 23, 24]. That is possible 
because of early implementation of genetic analysis for 
all the first-line family members on the basis of clinical 
presentation. Significantly lower age at MEN1 diagno-
sis was described by Pieterman [18], and this may be 
related to greater experience in management of MEN1 
patients at this centre (patients collected since 1978). 
Delays in the diagnosis of MEN1 are an important 
feature to evaluate, because it was claimed that earlier 
diagnosis improves the outcome [23–25]. Reducing 
the interval from symptoms to diagnosis appears to 
be crucial, especially in GEP-NETs, being the main 
cause of death in MEN1 patients [5, 26]. It is difficult to 
compare our data with other papers concerning that 
problem because there are differences in methodology. 
Table IV. Odds ratios of impact of type of mutations and involved exons on the analysed clinical events
Clinical event Risk factor OR 95% CI p-value
PNP Nonsense 0.69 (0.12, 3.94) 0.681
PNP Missense 0.61 (0.13, 2.94) 0.54
PNP Frameshift with STOP codon 1.81 (0.2, 16.18) 0.595
PNP Splicing NA NA NA
PNP Duplication NA NA NA
PNP Exon 0.92 (0.71, 1.19) 0.537
GEP-NET Nonsense 1.09 (0.37, 3.2) 0.879
GEP-NET Missense 0.82 (0.33, 2.01) 0.658
GEP-NET Frameshift with STOP codon 1.09 (0.37, 3.2) 0.879
GEP-NET Splicing 0.95 (0.06, 15.72) 0.97
GEP-NET Duplication NA NA NA
GEP-NET Exon 0.98 (0.85, 1.14) 0.805
PA Nonsense 0.72 (0.24, 2.16) 0.563
PA Missense 0.58 (0.23, 1.44) 0.236
PA Frameshift with STOP codon 3.5 (1.09, 11.23) 0.035
PA Splicing NA NA NA
PA Duplication NA NA NA
PA Exon 0.93 (0.8, 1.08) 0.343
PNP — primary hyperparathyroidism; GEP-NET — gastroenteropancreatic neuroendocrine tumours; PA — pituitary adenoma; NA — not assessed tumours;  
PA — pituitary adenoma
Figure 3. Prevalence MEN1 gene exons involved in mutations. Exon 6 was not involved in mutation in our database
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Yamazaki et al. reported delays of MEN1 diagnosis from 
–2.9 to 5.3 years, depending on different signs, tumours 
and proband/family member status [24]. Giudici et al. 
observed 5.7 years of delay from GEP-NET to MEN1 
diagnosis, which is significantly longer than observed in 
our database [27]. Leeuvaarde et al. described markedly 
longer delays in diagnosis of particular lesions, but the 
authors analysed only non-index cases, and the delays 
decreased in the course of time [23]. Our data reveal 
delays from –0.73 to 3.2 years depending on the tumour 
and index case/family member status. We observed 
the longest delays in PHP, which may be caused by 
non-specific or lack of symptoms and poor differentia-
tion between sporadic PNP and PNP associated with 
genetic syndrome.
We reported similar prevalence of main MEN1-re-
lated tumours to that observed previously in other 
populations [4, 13–18]. Surprisingly, we found a slightly 
lower percentage of functional pNETs with a markedly 
lower incidence of gastrinoma and higher incidence of 
insulinoma [13, 14, 17, 28]. The rare use of endoscopic 
ultrasound (EUS) in one of our centres is one of the 
possible explanations of the minor underdiagnosis of 
pNET in our cohort, especially considering the fact that 
EUS has been described to be one of the most accurate 
tools to diagnose pNETs [6, 29]. The prevalence of 
insulinoma and gastrinoma observed in other studies 
(11–22% and 26–56%, respectively) suggests that we 
underdiagnosed gastrinoma. We based the diagnosis 
of gastrinoma on clinical symptoms and biochemical 
tests, including fasting serum chromogranin A and 
gastrin levels. We did not imply (as recommended in 
guidelines) selective arterial secretagogue injection test 
and evaluation of basal acid output, which could lead 
to low prevalence of gastrinoma [1 ,30]. Moreover, it can 
be assumed that in Poland patients with gastrinoma 
are treated by other specialists such as surgeons and 
gastrologists, which could also have an impact on the 
percentage of observed gastrinomas in our database. 
On the other hand, it is the second study to observe 
higher prevalence of insulinoma in Polish patients 
with MEN1 syndrome, and it may be a feature of this 
population [22]. Importantly, we analysed only pa-
tients with MEN1 gene mutations, which could have 
an impact on reported percentages of typical tumours 
in comparison to other populations where also patients 
with clinical diagnosis and negative genetic mutation 
were analysed [4]. 
Many researchers have attempted to find a geno-
type-phenotype correlation in MEN1 syndrome [31–33]. 
Despite all these reports, clear correlation of clinical 
presentation and genotype has not been established 
in MEN 1 syndrome [34]. One of the most important 
findings of our research is a statistically significant, 
3.5-fold higher risk of developing a pituitary adenoma 
when a frameshift mutation with a STOP codon is pres-
ent. Considering our finding we should carefully seek 
pituitary tumours in patients with a frameshift muta-
tion with a STOP codon, but further studies including 
larger groups of patients are needed to establish strong 
recommendations.
A limitation of our work is the cohort size, which is 
relatively small compared to other papers regarding this 
subject. Nevertheless, the sample of the Polish popula-
tion with MEN1 syndrome analysed in our research is 
more than three-fold larger than previously analysed 
by Krassowski. Being tertiary referral centres, we are 
aware of the possibility of selection bias as we usually 
treat patients with advanced diseases from the whole 
Poland.
Nonetheless, considering the rarity of the disease, 
we believe that it is a meaningful contribution not only 
to describe the Polish population of MEN1 patients but 
also to general knowledge about the syndrome. More-
over, we assume that the publication of these findings 
will encourage other clinicians treating MEN1 in Poland 
to cooperate, which will result in analysis of a larger 
cohort in the future and decrease or even eliminate 
the selection bias. 
Conclusions
The Polish population with MEN1 syndrome is dif-
ferent from previously described populations, espe-
cially considering lower prevalence of functional pNETs 
among which insulinoma was dominant. Patients 
with frameshift mutations with a STOP codon of the 
MEN1 gene are at 3.5-fold higher risk of developing 
a pituitary tumour, and for that reason they should be 
carefully followed up for this tumour. Further studies 
with a larger cohort of patients should be performed to 
establish more precise data about the Polish population 
with MEN1 syndrome.
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